November 9, 2020
CellCarta’s poster presents a validated flow cytometry panel for the clinical monitoring of multiple myeloma (MM) patients. The MM Counting Panel detects and phenotypes malignant and non-malignant plasma cells, T cells, B cells, monocytes, and NK cells using fluorochrome-conjugated antibodies.
Key Features of the MM Counting Panel:
Assay Development and Characterization:
Conclusion: The MM Counting Panel, validated for clinical use, allows for robust and reliable monitoring of multiple myeloma patients. This comprehensive approach combines flow cytometry and mass spectrometry to enhance the detection of key biomarkers, supporting the development of novel therapies and optimizing treatment outcomes.
Multiple Myeloma Flow Cytometry Panel Validated for Clinical Monitoring of Patients
As presented in SITC 2020
View the full posterCellTalk Blog
September 18, 2024
Flow Cytometry
More infoCellTalk Blog
May 22, 2024
Flow Cytometry
More infoPosters
May 3, 2024
Flow Cytometry
More info